Evaluation of GLG-302, a STAT3 Antagon
$395,906N03FY2013CANIH
University Of Alabama At Birmingham, Birmingham AL
Investigators
Abstract
The primary goal of this task order is to determine whether GLG-302 (an inhibitor of STAT3 signaling) has cancer chemopreventive efficacy in preclinical models of breast cancer.
View original record on NIH RePORTER →